HOE pharmaceuticals Sdn. Bhd. Report issue

For profit Phase 4
Founded: Port Klang Malaysia (1969)
Status: No NME R&D (1969)

Organization Overview

First Clinical Trial
2020
NCT04325490
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

HOE pharmaceuticals Sdn. Bhd.

Active Ingredients

Drugs in Phase 4 Trials (1)

hydrocortisone (solu-cortef) (1 trial)

Drugs in Other Trials (1)

mometasone (elocon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Intertrigo (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2